Lack of association of angiotensin II type 1 receptor A1166C gene polymorphism with the risk of end-stage renal disease

References

• Marson BP, de Figueiredo CE, Tanus-Santos JE. Imbalance matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target. Basic Clin Pharmacol Toxicol. 2012;110:409–415
   PubMedGoogle Scholar
• Trabulus S, Guven GS, Altiparmak MR, et al. DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease. Mol Biol Rep. 2012;39:6995–7001
   PubMed Web of Science ®Google Scholar
• Prakash S, Prasad N, Sharma RK, et al. Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease. Cytokine. 2012;58:261–266
   PubMed Web of Science ®Google Scholar
• Borkar M, Tripathi G, Sharma RK, et al. Chemokine (CCR) and fractalkine (CX3CR) receptors and end stage renal disease. Inflamm Res. 2011;60:399–407
   PubMed Web of Science ®Google Scholar
• Alvarez R, Requero JR, Batalla A, et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res. 1998;40:375–379
   PubMed Web of Science ®Google Scholar
• Pontremoli R, Ravera M, Viazzi F, et al. Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension. Kidney Int. 2000;57:561–569
   PubMed Web of Science ®Google Scholar
• Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotension II receptor antagonists. Pharmacol Rev. 1993;45:205–251
   PubMed Web of Science ®Google Scholar
• Buraczynska M, Ksiazek P, Drop A, et al. Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrol Dial Transplant. 2006;21:979–983
   PubMed Web of Science ®Google Scholar
• Feng X, Zheng BS, Shi JJ, et al. A systematic review and meta-analysis of the association between angiotensin II type 1 receptor A1166C gene polymorphism and myocardial infarction susceptibility. J Renin Angiotensin Aldosterone Syst. 2012 Nov;e0:1--9
   Google Scholar
• Zsom M, Fulop T, Zsom L, et al. Genetic polymorphisms and the risk of progressive renal failure in elderly Hungarian patients. Hemodial Int. 2011;15:501–508
   PubMed Web of Science ®Google Scholar
• Coll E, Campos B, Nunez DG, et al. Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency. J Nephrol. 2003;16:357–364
   PubMed Web of Science ®Google Scholar
• Chang HR, Cheng CH, Shu KH, et al. Study of the polymorphism of angiotensinogen, anigiotensin-converting enzyme and angiotensin receptor in type II diabetes with end-stage renal disease in Taiwan. J Chin Med Assoc. 2003;66:51–56
   PubMedGoogle Scholar
• Papp F, Friedman AL, Bereczki C, et al. Renin-angiotensin gene polymorphism in children with uremia and essential hypertension. Pediatr Nephrol. 2003;18:150–154
   PubMedGoogle Scholar
• Lau YK, Woo KT, Choong HL, et al. Renin-angiotensin system gene polymorphisms: its impact on IgAN and its progression to end-stage renal failure among Chinese in Singapore. Nephrol Physiol. 2004;97:1–8
   Google Scholar
• Huang HD, Lin FJ, Li XJ, et al. Genetic polymorphisms of the renin–angiotensin–aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy. Chin Med J. 2010;123:3238–3242
   PubMed Web of Science ®Google Scholar
• Lee KB, Kim UK. Angiotensinogen and angiotensin II type 1 receptor gene polymorphism in patients with autosomal dominant polycystic kidney disease: effect on hypertension and ESRD. Yonsei Med J. 2003;44:641–647
   PubMedGoogle Scholar
• Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension. 1994;24:63–69
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang H, Qin H, Zhang K. Angiotensin II type I receptor A1166C polymorphism increases the risk of pregnancy hypertensive disorders: evidence from a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2012 Dec;e0:1--8
   Google Scholar
• Zhang K, Zhou B, Zhang L. Association study of angiotensin II type 1 receptor: A1166C (rs5186) polymorphism with coronary heart disease using systematic meta-analysis. J Renin Angiotensin Aldosterone Syst. 2013;14:181--188
   Google Scholar
• Ding W, Wang F, Fang Q, et al. Association between two genetic polymorphisms of the renin-angiotensin-aldosterone system and diabetic nephropathy: a meta-analysis. Mol Biol Rep. 2012;39:1293–1303
   PubMedGoogle Scholar
• Zhang H, Sun M, Sun T, et al. Association between angiotensin II type 1 receptor gene polymorphism and ischemic stroke: a meta-analysis. Cerebrovasc Dis. 2011;32:431–438
   PubMedGoogle Scholar
• Xu M, Sham P, Ye Z, et al. A1166C genetic variation of the angiotensin II type 1 receptor gene and susceptibility to coronary heart disease: collaborative of 53 studies with 20435 cases and 23674 controls. Atherosclerosis. 2010;213:191–199
   PubMedGoogle Scholar
• Hunley TE, Julian BA, Phillips JA, et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int. 1996;49:571–577
   PubMed Web of Science ®Google Scholar
• Pei Y, Scholey J, Thai K, et al. Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Inves. 1997;100:814–820
   PubMed Web of Science ®Google Scholar
• Frimat L, Philippe C, Maghakian MN, et al. Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS-a study of 274 men. J Am Soc Nephrol. 2000;11:2062–2067
   PubMed Web of Science ®Google Scholar
• Lau YK, Woo KT, Choong HL, et al. ACE gene polymorphism and disease progression of IgA nephropathy in Asians in Singapore. Nephron. 2002;91:499–503
   PubMed Web of Science ®Google Scholar
• Kim SM, Chin HJ, Oh YK, et al. Blood pressure-related genes and the progression of IgA nephropathy. Nephron Clin Pract. 2009;113:301–308
   Google Scholar